// App-Quantinova.ai

ABS156 : PERIOPERATIVE MANAGEMENT OF PATIENTS WITH HEMOPHILIA (PWH) RECEIVING FITUSIRAN PROPHYLAXIS WITH REDUCED DOSES OF BPA OR FACTOR REPLACEMENT

Researchers

Presenter

  • M. V. Ragni

Principal Investigators

  • S. W. Pipe

  • J. Pasi

  • C. Ngrier

  • P. Georgiev

  • T. Lissitchkov

  • S. Kichou

  • B. Mei

  • S. Andersson

Medical Centers

  • Department of Medicine, T

  • Hemophilia Center of Western Pennsylvania, University of Pittsburgh, Pittsburgh, PA

  • Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, United States

  • Royal London Haemophilia Centre, Barts and the London School of Medicine and Dentistry, London, United Kingdom

  • Unité d’Hémostase Clinique, Centre Régional de Traitement de l’Hémophilie, Hôpital Louis Pradel, Lyon, France

  • St George University Hospital for Active Treatment

  • Medical University of Plovdiv, Plovdiv

  • National Hospital for Active Therapy of Hematological Diseases, Sofia, Bulgaria

  • Sanofi, Cambridge, United States

Locations

  • United States

  • United Kingdom

  • France

  • Bulgaria

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Hemophilia

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02554773

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved